Dynacure

Dynacure is a clinical-stage company headquartered in Strasbourg, France, with a corporate office in Jenkintown, Pennsylvania. Employing six individuals, Dynacure focuses on researching and developing innovative therapies for rare diseases. Dynacure's primary focus is developing DYN101, an antisense product candidate in collaboration with Ionis Pharmaceuticals. DYN101 is designed to reduce the expression of dynamin 2 protein, offering potential treatment for Myotubular and Centronuclear Myopathies. The company is also developing DYN201, a program targeting Hereditary Spastic Paraplegias. Dynacure is dedicated to improving the lives of patients with limited or no treatment options for their rare diseases. Their work spans both its lead program, DYN101, and its complementary research portfolio, which includes the DYN201 program. For inquiries, visit Dynacure's website at dynacure.fr.